EyePoint Pharmaceuticals, Inc. — Director's Dealing 2018

Oct 29, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2018-10-25

Reporting Person: Landis John B. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-25	Employee Stock Option (right to buy)	$2.27	A	80000	Acquired	2028-10-25	Common Stock (80000)	Direct

Footnotes

F1: The option becomes exercisable in three equal annual installments beginning on October 25, 2019.